The National Organization for Rare Disorders is urging lawmakers to oppose House Democrats’ legislative proposal that would limit the number of rare disease drugs that can qualify for tax credits under the Orphan Drug Act. NORD says the proposal, included in the House Ways & Means Committee’s reconciliation package to be marked up this week, would remove critical incentives for rare disease drug makers, especially smaller companies that focus exclusively on orphan drugs. NORD says it’s deeply concerned about what...